Terms: = Endocrine gland cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK
2159 results:
1. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
Chen Y; Xiao X; Hu G; Liu R; Xue J
J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
[TBL] [Abstract] [Full Text] [Related]
2. pH-responsive targeted nanoparticles release erk-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
[TBL] [Abstract] [Full Text] [Related]
3. Biological functions of LncRNA SNHG14 in the development of thyroid cancer cells via targeting miR-206.
Sang Y; Min R; Huang T; Zhang J
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):77-84. PubMed ID: 38678623
[TBL] [Abstract] [Full Text] [Related]
4. IFNα-induced BST2
Zheng C; Wang J; Zhou Y; Duan Y; Zheng R; Xie Y; Wei X; Wu J; Shen H; Ye M; Kong B; Liu Y; Xu P; Zhang Q; Liang T
Cell Rep; 2024 Apr; 43(4):114088. PubMed ID: 38602878
[TBL] [Abstract] [Full Text] [Related]
5. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B
Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093
[TBL] [Abstract] [Full Text] [Related]
6. TIM3 activates the erk1/2 pathway to promote invasion and migration of thyroid tumors.
Jin X; Yin Z; Li X; Guo H; Wang B; Zhang S; Li Y
PLoS One; 2024; 19(4):e0297695. PubMed ID: 38568917
[TBL] [Abstract] [Full Text] [Related]
7. A senescence restriction point acting on chromatin integrates oncogenic signals.
Lopes-Paciencia S; Bourdeau V; Rowell MC; Amirimehr D; Guillon J; Kalegari P; Barua A; Quoc-Huy Trinh V; Azzi F; Turcotte S; Serohijos A; Ferbeyre G
Cell Rep; 2024 Apr; 43(4):114044. PubMed ID: 38568812
[TBL] [Abstract] [Full Text] [Related]
8. TRIM29 facilitates gemcitabine resistance via MEK/erk pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.
Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y
Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727
[TBL] [Abstract] [Full Text] [Related]
9. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer.
Bulle A; Liu P; Seehra K; Bansod S; Chen Y; Zahra K; Somani V; Khawar IA; Chen HP; Dodhiawala PB; Li L; Geng Y; Mo CK; Mahsl J; Ding L; Govindan R; Davies S; Mudd J; Hawkins WG; Fields RC; DeNardo DG; Knoerzer D; Held JM; Grierson PM; Wang-Gillam A; Ruzinova MB; Lim KH
Nat Commun; 2024 Mar; 15(1):2503. PubMed ID: 38509064
[TBL] [Abstract] [Full Text] [Related]
10. ACA-28, an erk MAPK Signaling Modulator, Exerts Anticancer Activity through ROS Induction in Melanoma and Pancreatic cancer Cells.
Takasaki T; Hamabe Y; Touchi K; Khandakar GI; Ueda T; Okada H; Sakai K; Nishio K; Tanabe G; Sugiura R
Oxid Med Cell Longev; 2024; 2024():7683793. PubMed ID: 38500550
[TBL] [Abstract] [Full Text] [Related]
11. Carcinoma showing thymus-like elements (CASTLE) with amyloid deposition in the parotid gland.
Hamada M; Miyama Y; Matsumura S; Shintani-Domoto Y; Urano M; Yasuda M
Pathol Int; 2024 Apr; 74(4):227-233. PubMed ID: 38488752
[TBL] [Abstract] [Full Text] [Related]
12. Unveiling the role of PYGB in pancreatic cancer: a novel diagnostic biomarker and gene therapy target.
Ren LK; Lu RS; Fei XB; Chen SJ; Liu P; Zhu CH; Wang X; Pan YZ
J Cancer Res Clin Oncol; 2024 Mar; 150(3):127. PubMed ID: 38483604
[TBL] [Abstract] [Full Text] [Related]
13. Lactate enhances NMNAT1 lactylation to sustain nuclear NAD
Huang H; Wang S; Xia H; Zhao X; Chen K; Jin G; Zhou S; Lu Z; Chen T; Yu H; Zheng X; Huang H; Lan L
Cancer Lett; 2024 Apr; 588():216806. PubMed ID: 38467179
[TBL] [Abstract] [Full Text] [Related]
14. Circ-LDLRAD3/miR-655-3p/mapk1 axis enhances cell migration and invasion in papillary thyroid carcinoma.
Zhang B; Peng Y; Zhou L
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):150-155. PubMed ID: 38430029
[TBL] [Abstract] [Full Text] [Related]
15. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
[TBL] [Abstract] [Full Text] [Related]
16. VNP20009-Abvec-Igκ-MIIP suppresses ovarian cancer progression by modulating Ras/MEK/erk signaling pathway.
Wang Q; Tang Y; Dai A; Li T; Pei Y; Zhang Z; Hu X; Chen T; Chen Q
Appl Microbiol Biotechnol; 2024 Feb; 108(1):218. PubMed ID: 38372808
[TBL] [Abstract] [Full Text] [Related]
17. Integrated bioinformatics approaches and expression assays identified new markers in pituitary adenomas.
Motlagh PE; Jamali E; Karimi N; Eslami S; Sharifi G; Ghafouri-Fard S
Pathol Res Pract; 2024 Mar; 255():155193. PubMed ID: 38364650
[TBL] [Abstract] [Full Text] [Related]
18. Phosphorylation of PBK at Thr9 by CDK5 correlates with invasion of prolactinomas.
Fang Q; Liu C; Nie D; Guo J; Xie W; Zhang Y
CNS Neurosci Ther; 2024 Feb; 30(2):e14629. PubMed ID: 38363020
[TBL] [Abstract] [Full Text] [Related]
19. AKR1C3 silencing inhibits autophagy-dependent glycolysis in thyroid cancer cells by inactivating erk signaling.
Gao Y; Tao W; Wang S; Duan R; Zhang Z
Drug Dev Res; 2024 Feb; 85(1):e22142. PubMed ID: 38349266
[TBL] [Abstract] [Full Text] [Related]
20. Inhibition of the RAF/MEK/erk Signaling Cascade in Pancreatic cancer: Recent Advances and Future Perspectives.
Adamopoulos C; Cave DD; Papavassiliou AG
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
[TBL] [Abstract] [Full Text] [Related]
[Next]
